A new long acting ophthalmic formulation of Carteolol containing alginic acid

Polysaccharides as Excipients for Ocular Topical Formulations

“…In vitro studies indicated that carteolol is released slowly from mucoadhesive AA formulations, suggesting an ionic interaction between the basic drug and AA. IOP measurements of rabbit eyes treated with a 1% carteolol formulation with or without AA showed that this polymer significantly extended the duration of the IOP-reducing effect to 8 h. AA produced an ocular bioavailability increase of a carteolol formulation, as indicated by a drug concentration in the target tissue, following a once-daily administration, equivalent to a twice-daily administration of the AAfree carteolol solution (Sechoy et al, 2000).…”

Newer Trends in In Situ Gelling Systems for Controlled Ocular Drug Delivery

“…Sechoy et al [22], compared alginic acid and hydroxyethylcellulose (HEC) as in situ gelling system for prolonged delivery of carteolol. However, the viscosity of both alginic acid and HEC based formations was almost similar but the alginic acid showed slower in vitro drug diffusion of carteolol and better adhesive properties with mucin coated corneal surface as compared to HEC.…”

“…The peak plasma concentration of carteolol was lower for alginic acid formulations as compared to plain carteolol solution. The alginic acid based in situ gelling systems are able to reduce the frequency of carteolol dosing from twice to only once a day [22].…”

“…Interestingly the gels were much better retained in the human eyes as compared to that of rabbit's eyes. The ocular residence time of gels is depend on the rheological properties and viscosity [21,22,42]. The gels showed high elasticity, which was concentration independent at 0.6% gelrite ® and above, suggesting longer precorneal contact times.…”

“…A wide variety of drug molecules and materials of therapeutic advantages such as antibiotics (Ofloxacin, Ciprofloxacin, Gatifloxacin), beta blockers (Timolol, Carteolol), NSAIDs (Ketorolac Tromethamine, Indomethacin), Pilocarpine hydrochloride, Puerarin, Recombinant rhEGF, Antivirals (Acyclovir) has been delivered through in situ gelling systems, which shows the importance of in situ gelling formulations as the future drug delivery systems [7][8][9][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25].…”